Agennix Lung Cancer Drug in Doubt After Clinical Trial Failure Bloomberg “We are extremely disappointed and surprised with today's results, especially considering the earlier promising results we had seen in two randomized Phase II trials with talactoferrin alfa in non-small cell lung cancer,” said Rajesh Malik, chief ... |
